Background: For palliative care settings, little is known about the benefits of specific methicillin-resistant Staphylococcus aureus containment regimens and the burdens patient isolation imposes on affected patients, their families, and professional caregivers. Aim: To explore the current practice of MRSA management and its impact on inpatients' quality of life as perceived by professional caregivers. Design: Survey of inpatient palliative care institutions using 23-item questionnaires (infrastructural data: six items, management process: 14, clinical significance: three). Setting/participants: All palliative care units (179) and hospices (181) listed in Germany's directory of palliative care services. The c 2 test was used to test for differences; significance level: p ≤ 0.05. Results: 229 of 360 questionnaires were returned. More than 90% of the responding institutions employed specific MRSA protocols. Lack of resources was a more important issue for palliative care units than for hospices regarding availability of single rooms (p = 0.002) and staffing (p = 0.004). Compared to hospices, palliative care units more frequently isolated MRSA patients (p = 0.000), actively treated colonization (p = 0.026), assessed the efficacy of eradication (p = 0.000), provided information on MRSA management to patients (p = 0.014) and relatives (p = 0.001), more often restricted patients' activities (p = 0.000), and reported a negative impact on quality of life (p = 0.000). Conclusions: Rigorously applied MRSA protocols impose significant burdens at the end of life. Research on clinical outcomes including quality of life may identify interventions of questionable benefit. The issue of handling MRSA should be studied as a model for the management of other highly complex conditions and special needs such as patient isolation.
Introduction
In patients with far advanced disease, all interventions aim at optimal palliation of symptoms and enhancement of quality of life. For palliative care units (PCU) and hospices, the emergence of microbial strains highly resistant to antiinfective therapy such as MRSA poses an additional challenge, as regimens that prevent MRSA transmission impose barriers and restrictions on patients and their relatives adversely affecting patient related outcomes. 1, 2 Although prevalence numbers in Germany are currently stable, 3 MRSA remains a serious health care issue throughout Europe, still being the most commonly identified antibiotic-resistant pathogen in European hospitals. 4 Thus, rigorous application of such protocols may be essential for infection control but at the same time could jeopardize therapeutic efforts of palliative care.
Given the ethical dilemma of acting according to the principle of patient safety (applying efficient isolation measures) and with respect to one of the main principles of palliative care (social inclusion of the dying), surprisingly only one survey on MRSA management in the palliative care setting has been published so far. This study explored the policies of MRSA containment in 63 southern England PCUs and hospices. 5 While almost all of the institutions required their staff to take infection control precautions and employed a formal MRSA protocol, a lesser proportion of these enacted some kind of isolation on patients with known or suspected MRSA infection or restricted their activities within the unit, and there was still a lower figure for MRSA screening on admission. Specific procedures varied between the units and according to MRSA status of the patient. Among hospices in particular, there were doubts on the relevance of such protocols and divergent opinions on their impact on patients' quality of life. The authors conclude that there may be systematic underreporting of MRSA prevalence but suggest that 'a more stringent approach… could only increase the number of patients potentially disadvantaged by the burden of eradication treatment'. 5 Regarding screening, a recent, large prospective casecontrol study in the US found that universal screening on admission did not reduce the rate of hospital-acquired MRSA infection compared to a targeted approach and was not cost beneficial. 6 Furthermore, little is known on how prevalent MRSA is in PCUs or hospices. Of three studies, one observed a colonization prevalence of 4-8% in a retrospective chart review of three different hospices in London. 7 Another group surveyed a single hospice -also in London -using an observational design. They found that 9.2% of patients admitted from settings with unknown MRSA presence had MRSApositive swabs at some point during their hospice stay, while 7.1% from wards with known MRSA background tested positive. 8 These figures are lower than the prevalence rates of 17% 9 to 23% 10 found in UK nursing home residents and similar to the rate of 7.8% 11 seen in patients with dementia living in care homes.
We then raised the question whether these findingsperception of rather questionable benefits of specific MRSA protocols coupled with significant side effectswould be observed in German PCUs and hospices as well. Therefore, we conducted a nationwide questionnaire-based survey to assess current practice of MRSA management and its impact on patients and relatives as perceived by the professional staff. Of particular interest were the differences in perception between the two types of institutions (PCU and hospice) and how these viewpoints translated into institution-specific strategies. *
Methods
To obtain a broad scope of existing MRSA policies in German palliative care units and to avoid selection bias, all PCUs and hospices in Germany were contacted by mail in January 2009. If no response was received by the end of February 2009, an electronic reminder was sent to the institution. To ensure confidentiality and further minimize bias, data processing was planned after de-identification of the respondents.
Ethical issues were discussed within the study group. Formal approval from the institutional review board was not considered necessary, as no data were collected from patients or relatives.
A structured, 23-item questionnaire was developed on the grounds of translation and modification of the original tool used by Dand et al. 5 consisting principally of closed questions with tick box answers. Six items covered basic infrastructural data, 14 elucidated the MRSA containment policy of each institution, and three looked into attitudes towards use and views of such policies. In the infrastructural section, questions asked for the type of institutioneither PCU or hospice (1), total number of beds (2), number of single rooms (3), current number of occupied beds (4), median length of stay (5) , and current number of patients with known MRSA positivity (6) . In the policy section, information was requested regarding existence of a formal MRSA protocol (7) , barriers to admission or discharge of MRSA-positive patients (8) , routine MRSA screening on admission (9), isolation of MRSA-positive patients (10), precautions taken by staff caring for MRSA-positive patients (11) , MRSA screening of staff (12) , information policy for MRSA-positive patients (13) and visitors (14) , preventive measures for visitors (15) , restrictions of mobility and social activities of MRSA-positive patients (16) , treatment policy of MRSA colonization (17), possible contraindications against MRSA eradication therapy (18), laboratory control of MRSA eradication therapy (19) , and screening on re-hospitalization of a formerly MRSApositive patient (20) . In the final section on clinical relevance, questions asked whether an existing MRSA protocol was adhered to (21) , whether respondents felt such a protocol would influence the patients' quality of life (22) , and whether eradication protocols were of importance for inpatient treatment in PCUs or hospices (23) .
In the majority of items (8-16, 18, 22-23) , the respondents were asked to specify their answers by ticking all appropriate boxes from a checklist. To gain a deeper understanding of relevant factors not explicitly asked for in the questions, we provided blank space for additional free-listing of detailed comments.
Item 1 allowed for stratification of the data according to type of institution. Thus, we were able to calculate separate figures for PCUs and hospices, respectively, and to compare the results. Data processing and analyses were performed using commercial statistics software (IBM SPSS Statistics 18). Responses were compared using the χ 2 test, significant differences were assumed at p values ≤ 0.05.
Results
In total, 360 institutions (179 PCUs and 181 hospices) were contacted. About 65% of the PCUs (n = 117) and 62% of the hospices (n = 112) responded, resulting in 229 evaluable data sets. Table 1 shows the results of the first six questionnaire items covering basic infrastructural characteristics of the institutions. PCUs and hospices were roughly of the same size and had similar occupancy rates. However, they differed regarding the number of single rooms (6/8 and 9/9, respectively) and median length of stay (11 and 21 days, respectively). Table 2 provides an overview of the findings in the policy section of the questionnaire.
In both types of institutions -PCU and hospice -the large majority (96% and 92%, respectively) have established MRSA containment guidelines ('protocol', item 7), while PCUs face significantly more barriers to admission or discharge of MRSA-positive patients than hospices (37% vs 22%, p = 0.012), partly because of shortage of isolation facilities (15% vs 3%, p = 0.002) and personnel (16% vs 5%, p = 0.004, item 8). Compared with hospices, a higher percentage of PCUs screen their patients for MRSA colonization (32% vs 4%, p =.000), but some perform the screening only if specific risk factors, such as wounds or catheters, are present or the referring institution is known to host MRSA carriers (item 9). PCUs more probably isolate MRSA-positive patients (99% vs 76%, p = 0.000), in particular those with a prior history of MRSA, a positive swab on referral, specific risk factors, or a risk of MRSA transmission, while ethical reasons not to isolate a patient play a role more often in hospices (item 10). In both types of institutions, staff were usually obliged to take precautionary measures (item 11). A variety of specific actions were listed, such as disinfection and separation of contaminated waste. MRSA screening of staff (27% vs 9%, p = 0.001) was performed to a lesser and variable extent (item 12). More than two thirds of all institutions provided specific information to patients (82% vs 67%, p = 0.014, item 13) and visitors (99% vs 89 %, p = 0.001, item 14), but a higher ratio of PCUs handed out written material. Most institutions recommended precautionary measures for visitors of MRSA-positive patients (item 15), while protective devices like disposable gloves, gowns and face masks were used more commonly in PCUs than in hospices. PCUs more often restricted MRSA-positive patients' activities, such as accessing recreational and dining rooms, contacting other patients, mobility within the hospital, and participation in certain therapies (96% vs 66%, p = 0.000, item 16), and they more commonly applied MRSA eradication regimens in patients with MRSA colonization (71% vs 27%, p = 0.026, item 17). In both types of institution, there was practical experience to abstain from eradication under certain conditions such as imminent death, confusion, prior eradication failure, inability to give consent, or refusal of eradication therapy (item 18). Both routine laboratory confirmation of successful eradication (97% vs 61%, p = 0.000, item 19) and a repeat swab on readmission of a known MRSA carrier patient (83% vs 19%, p = 0.000, item 20), were performed more commonly in PCUs than in hospices. Table 3 shows the results of the section on clinical relevance, as perceived by staff.
Adherence to an existing MRSA protocol was reported to be stricter by the responding PCUs than the hospices (46% vs 27%, p = 0.010, item 21). The negative impact of these protocols on the quality of life of the affected patients was estimated higher by PCU staff than by hospice staff (83% vs 55%, p = 0.000, item 22); in particular, social deprivation and emotional barriers as an effect of isolation were noted. About half of all institutions reported significant effects of such protocols (item 23) which were related to performance status, mobility, and future treatment repeat swab on readmission 89 (83) 11 (19) .000
options of the individual patient. Furthermore, the degree to which the PCU or hospice was embedded in a larger institution facilitating further MRSA transmission played a role in perception of clinical relevance and in decision-making. The answers given in the free-listing sections of items 8-16, 18, and 22-23 provided additional aspects to each question; the most frequent comments are summarized above in the results of the respective item. In general, a wide variety of comments regarding infrastructure, clinical management, policy, ethics, and personal perceptions were made.
Discussion
In this large questionnaire-based survey of all German PCUs and hospices, we found MRSA protocols present and available in the large majority of both types of institution. Among these, however, the number of 'active users' at daily practice level is considerably smaller, which is particularly evident in hospices. Our survey revealed significant differences between PCUs and hospices in terms of structural barriers and MRSA containment policies. In general, the self-reported adherence to protocols was stricter in PCUs, with tighter restrictions on patients, visitors and staff, compared to the more liberal hospice policy. Even though exclusion criteria for eradication therapy did not differ between both types of institution, PCU staff members more commonly perceived a negative impact of MRSA protocols on the patient's quality of life. These findings reveal perceptions of widespread uncertainty among palliative care staff members regarding MRSA management and marked differences between PCU and hospice policies.
Limitations of the study are of a methodological nature. First, the data are self-reported by the respondents; this methodology is not equivalent to direct observation by the researchers. Second, linkages of phenomena to either causes or effects are not supported by the data. For example, neither the reasons for the inter-institutional differences nor the effects of different policies on the professional teams can be determined. Third, the scope of the survey was limited by the fact that only members of the professional teams were approached (without asking which professions participated in answering the questions) but not family members or patients themselves. Thus, the effects of more or less rigid MRSA regimens on patient-related outcomes, such as incidence of MRSA colonization, quality of life, and overall satisfaction, could not be measured directly. Moreover, we do not know the non-responders' characteristics, their MRSA-related policies, and the reasons why they did not participate.
Among the strengths of our survey is, first of all, the large sample size including all German providers of specialized inpatient palliative care (in total, 360 units) and the high response rates of 65% and 62% (for PCUs and hospices, respectively). Second, the UK questionnaire, which served as a template for our translation, had been found useful to obtain insight into MRSA management in the palliative care setting in a smaller study previous to our survey. 5 Third, we add a trans-cultural view to the previous UK findings by performing the survey in a country with a different language background and by stratification according to the two most common types of palliative care institutions in Germany. This design enabled us to compare the findings of PCUs with those of hospices.
German MRSA guidelines published in 1999 and updated in 2008 include instructions on MRSA detection and eradication, patient isolation measures, staff education, and adherence to sanitation protocols 13, 14 and resemble their counterparts in neighbouring countries. In 2008, the reported MRSA prevalence was decreasing on a European level 4 and even reached the lowest reported numbers since 1999 in some countries, 15 but differences between national surveillance policies make direct comparisons difficult, and the reported rather than actual levels may not capture the entire picture. Nevertheless, MRSA currently remains a publicly debated 16 major health care issue, particularly in intensive care units 3 and large teaching hospitals. 17 A substantial number of palliative care patients are referred from those units accounting for the MRSA prevalence in PCUs and hospices, while community-acquired MRSA contributes as well. However, data on this population are lacking almost entirely, while some groups have explored outcomes and side effects of MRSA management in a general inpatient population. Two Swedish qualitative interview studies and a cross-sectional matched control study from the UK revealed that living with MRSA and its therapeutic implications could be extremely stressful 1 and traumatic 2 for the affected patients and negatively affect their moods, 18 while others found little detrimental psychological effect of isolation. 19, 20 A North American cohort study raised the concern of inferior care of isolated patients, 21 and two observational studies from the US recorded significantly less health care provider/ patient contact in isolated than in non-isolated patients. 22, 23 The results of our global assessment of current MRSA containment policies in German palliative care institutions do add evidence from a professional caregivers' and institutional perspective to the cross-border notion of negative effects of such policies on patients both in the palliative care 5, 7, 8 and in other settings. 1, 2, 18 Next steps should begin with conducting a multi-centre mixed-method investigation of affected patients' and relatives' opinions on their experience of the MRSA regimen to estimate the magnitude of the problem within the palliative care settings. Second, clinical data obtained from carefully matched cohorts may clarify the significance of MRSA eradication, isolation protocols and treatment. Third, building on these data, a decision-making algorithm may be developed and validated to identify patients who possibly benefit from eradication therapy. As other multi-resistant organisms may emerge in the near future, the case of MRSA should be studied as a model for the management of patients with highly complex conditions and special needs such as isolation.
Our findings highlight the situation of very ill patients who are in need of very complex therapies. MRSA protocols, for example, do not uniquely confer beneficial effects but have to be weighed against possible drawbacks. Therapeutic dilemmas may arise between the concomitant needs for both comprehensive psycho-social care and anti-infective isolation. Guidelines for nursing homes in Germany, for example, recommend an approach ('standard sanitary measures') based on the Centers for Disease Control and Prevention Standard Precautions, 24 thus avoiding isolation and restriction of social activities. 25 The palliative care specialists' knowledge of how to handle severely ill or dying MRSApositive patients may reconcile conflicting needs, facilitate a more pragmatic approach to this vulnerable population, and foster timely referrals to PCUs and hospices.
